Artificial Intelligence-Detected Tumor-Infiltrating Lymphocytes as a Biomarker in Anti-PD-1-Based Therapy for Advanced Melanoma: Clinical Evidence and Translational Perspectives
Posted inAI Oncology Pathology & Lab Medicine Specialties

Artificial Intelligence-Detected Tumor-Infiltrating Lymphocytes as a Biomarker in Anti-PD-1-Based Therapy for Advanced Melanoma: Clinical Evidence and Translational Perspectives

AI-detected tumor-infiltrating lymphocytes on routine histology independently predict response and survival in advanced melanoma treated with anti-PD-1 therapies, outperforming manual scoring and offering an accessible biomarker for immune checkpoint inhibitor outcomes.
Standardizing Pathological Response Reporting After Neoadjuvant Therapy in Kidney Cancer: New International Guidelines
Posted inOncology Pathology & Lab Medicine Specialties

Standardizing Pathological Response Reporting After Neoadjuvant Therapy in Kidney Cancer: New International Guidelines

International experts issue consensus guidelines for sampling and reporting pathological response to neoadjuvant therapy in renal cell carcinoma, recommending standardized specimen sampling and quantification of residual viable tumor to enable reliable trial endpoints and future clinical use.
Clinical Decision Tool Integrating Decision Tree, Point-of-Care CRP Testing, and Safety Netting to Optimize Antibiotic Use in Acutely Ill Children: Evidence from the ARON Pragmatic Trial and Contextual Literature
Posted inClinical Updates Critical Care news Pathology & Lab Medicine Pediatrics Public Health Specialties

Clinical Decision Tool Integrating Decision Tree, Point-of-Care CRP Testing, and Safety Netting to Optimize Antibiotic Use in Acutely Ill Children: Evidence from the ARON Pragmatic Trial and Contextual Literature

The ARON trial demonstrated that a clinical decision tool combining decision tree, point-of-care CRP testing, and safety-netting advice safely reduces antibiotic prescribing in acutely ill children without delaying recovery or increasing healthcare utilization.
Early ctDNA Dynamics Predict Long-Term Survival in dMMR/MSI-H Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors
Posted inOncology Pathology & Lab Medicine Specialties

Early ctDNA Dynamics Predict Long-Term Survival in dMMR/MSI-H Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors

Change in circulating tumor DNA (ctDNA) one month after treatment initiation predicts progression-free and overall survival in patients with dMMR/MSI-H metastatic colorectal cancer receiving immune checkpoint inhibitors, offering a potential biomarker for therapeutic decision-making.